In Maryland, drug price controls won’t help patient affordability

At a time when Maryland could be accelerating medical innovation to meet the world’s health challenges, our state’s policymakers are taking steps that could curb medical advancements and disrupt patient access and care. The state’s Prescription Drug Affordability Board (PDAB), established in 2019, voted recently to start the process of imposing Upper Payment Limits (UPLs) on up to six medications that treat heart disease, diabetes, Crohn’s disease and more.